Novartis AG Common Stock (NY:NVS)

140.35 -0.65 (-0.46%)

Delayed Quote Updated: 9:39 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? ↗

August 23, 2026

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

Via MarketBeat

Topics ETFs

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.

Via The Motley Fool

Topics ETFs World Trade

Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors ↗

August 21, 2026

Via Chartmill

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗

August 18, 2026

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

Via The Motley Fool

Topics ETFs

Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts ↗

July 29, 2026

Via Chartmill

NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout ↗

July 07, 2026

Via Chartmill

PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗

August 18, 2026

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Via The Motley Fool

Topics ETFs

This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem ↗

August 17, 2026

The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. ↗

August 16, 2026

Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗

August 14, 2026

Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗

August 12, 2026

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

Via The Motley Fool

Topics ETFs

3 Dividend Stocks to Buy for a Lifetime of Passive Income ↗

July 29, 2026

These companies' recent headwinds shouldn't lead to decreased payouts.

Via The Motley Fool

Topics Intellectual Property

Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ ↗

July 23, 2026

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The...

Via The Motley Fool

Topics ETFs

Novartis (NVS) Q2 2026 Earnings Call Transcript ↗

July 21, 2026

Growth drivers offset generic erosion as priority brands surge 36% in constant currency.

Via The Motley Fool

Topics Earnings

Novartis Q2 Earnings Call Highlights ↗

July 21, 2026

Novartis (NYSE:NVS) said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite...

Via MarketBeat

Topics ETFs Earnings

Novartis Q2 2026 Earnings Call Transcript ↗

July 21, 2026

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access...

Via Benzinga

Topics Earnings

Novartis Bounds For Buy Point. Why Shares Are On The Rise. ↗

July 21, 2026

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.

Via Investor's Business Daily

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline ↗

July 21, 2026

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

Via Benzinga

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗

July 20, 2026

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Via The Motley Fool

Topics ETFs

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval ↗

July 17, 2026

Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney decline in adult IgAN.

Via Benzinga

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

July 14, 2026

New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease...

Via Newsfile

Global Nitrogen-Containing Bisphosphonate Drugs Market Growing at 3.1% CAGR Through 2032 ↗

July 14, 2026

According to a new report from Intel Market Research, the global Nitrogen-Containing Bisphosphonate Drugs Market was valued at USD 3.65 billion in 2024 and

Via Talk Markets

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 09, 2026

Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?

Via The Motley Fool

What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It? ↗

July 09, 2026

Not every international ETF is a can't-miss investment opportunity.

Via The Motley Fool

Topics ETFs Economy

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗

July 09, 2026

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Via The Motley Fool

Topics ETFs

VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗

July 09, 2026

When buying international dividend stocks, diversification is likely the best bet.

Via The Motley Fool

Topics Artificial Intelligence ETFs

2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗

July 08, 2026

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

Via The Motley Fool

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗

July 08, 2026

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition

July 06, 2026

Via Investor Brand Network

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push ↗

July 06, 2026

Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.